Insider Transactions in Q1 2024 at Ironwood Pharmaceuticals Inc (IRWD)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2024
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
1,662
+1.34%
|
-
|
|
Mar 08
2024
|
Thomas A Mccourt Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
120,298
+8.99%
|
-
|
|
Mar 08
2024
|
Andrew Davis SVP, Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,120
+10.67%
|
-
|
|
Mar 08
2024
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
BUY
Exercise of conversion of derivative security
|
Direct |
34,936
+7.52%
|
-
|
|
Mar 08
2024
|
Sravan Kumar Emany SVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,120
+9.87%
|
-
|
|
Mar 08
2024
|
Minardo John Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,752
+9.5%
|
-
|
|
Mar 06
2024
|
Jon R Duane |
BUY
Open market or private purchase
|
Direct |
6,920
+5.41%
|
$55,360
$8.7 P/Share
|
|
Mar 05
2024
|
Thomas A Mccourt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
264,876
+19.44%
|
-
|
|
Mar 04
2024
|
Sravan Kumar Emany SVP, Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,684
+3.42%
|
$96,156
$9.38 P/Share
|
|
Feb 12
2024
|
Minardo John Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,427
+16.31%
|
-
|
|
Feb 12
2024
|
Minardo John Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
47,380
-17.41%
|
$710,700
$15.24 P/Share
|
|
Feb 12
2024
|
Ronald Silver Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,213
+14.42%
|
-
|
|
Feb 12
2024
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
7,908
-5.56%
|
$118,620
$15.24 P/Share
|
|
Feb 12
2024
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
BUY
Grant, award, or other acquisition
|
Direct |
54,427
+12.11%
|
-
|
|
Feb 12
2024
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
SELL
Open market or private sale
|
Direct |
38,618
-10.19%
|
$579,270
$15.24 P/Share
|
|
Feb 12
2024
|
Andrew Davis SVP, Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,312
+19.27%
|
-
|
|
Feb 12
2024
|
Andrew Davis SVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
9,846
-4.51%
|
$147,690
$15.24 P/Share
|
|
Feb 12
2024
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
177,164
-17.54%
|
$2,657,460
$15.24 P/Share
|
|
Feb 12
2024
|
Sravan Kumar Emany SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,312
+18.33%
|
-
|
|
Feb 08
2024
|
Sravan Kumar Emany SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
41,332
-15.48%
|
$578,648
$14.9 P/Share
|
|
Jan 17
2024
|
Sravan Kumar Emany SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+24.14%
|
-
|
|
Jan 17
2024
|
Minardo John Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
79,981
+22.71%
|
-
|
|
Jan 17
2024
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
BUY
Grant, award, or other acquisition
|
Direct |
57,971
+13.26%
|
-
|
|
Jan 17
2024
|
Thomas A Mccourt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
249,617
+19.82%
|
-
|